Community Bank of Raymore Has $2.47 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Community Bank of Raymore lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 12.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,899 shares of the company’s stock after purchasing an additional 1,520 shares during the quarter. AbbVie makes up about 1.9% of Community Bank of Raymore’s holdings, making the stock its 18th biggest position. Community Bank of Raymore’s holdings in AbbVie were worth $2,470,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. Willner & Heller LLC increased its holdings in shares of AbbVie by 6.2% during the 4th quarter. Willner & Heller LLC now owns 8,448 shares of the company’s stock valued at $1,501,000 after acquiring an additional 491 shares during the last quarter. Pine Haven Investment Counsel Inc boosted its position in AbbVie by 1.4% during the fourth quarter. Pine Haven Investment Counsel Inc now owns 18,347 shares of the company’s stock worth $3,260,000 after purchasing an additional 245 shares during the period. Diversify Wealth Management LLC grew its holdings in AbbVie by 62.3% during the fourth quarter. Diversify Wealth Management LLC now owns 25,635 shares of the company’s stock valued at $4,491,000 after purchasing an additional 9,840 shares during the last quarter. RoundAngle Advisors LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $1,730,000. Finally, Grove Bank & Trust lifted its stake in shares of AbbVie by 2.2% in the fourth quarter. Grove Bank & Trust now owns 13,141 shares of the company’s stock worth $2,335,000 after buying an additional 282 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

AbbVie stock opened at $171.49 on Tuesday. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The stock has a fifty day moving average price of $175.78 and a two-hundred day moving average price of $184.75. The firm has a market capitalization of $303.05 billion, a P/E ratio of 59.55, a P/E/G ratio of 1.73 and a beta of 0.58.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.92 by $0.08. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.28 billion. AbbVie had a net margin of 9.22% and a return on equity of 244.01%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm posted $2.95 EPS. As a group, analysts anticipate that AbbVie Inc. will post 10.06 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be issued a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.83%. This is a boost from AbbVie’s previous quarterly dividend of $1.55. The ex-dividend date is Wednesday, January 15th. AbbVie’s dividend payout ratio (DPR) is currently 215.28%.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on ABBV shares. Piper Sandler Companies reiterated an “overweight” rating and issued a $220.00 target price on shares of AbbVie in a report on Tuesday, December 17th. Bank of America reiterated a “neutral” rating and issued a $191.00 price objective on shares of AbbVie in a research note on Tuesday, December 10th. Argus upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Monday, November 4th. UBS Group lifted their price target on AbbVie from $195.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, Wolfe Research assumed coverage on AbbVie in a research report on Friday, November 15th. They issued an “outperform” rating and a $205.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $205.50.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.